Immunotherapy
Dr Morganna Freeman breaks down her methods for explaining immunotherapy to her patients. Read More ›
Dr Morganna Freeman discusses some of the ways immunotherapy has changed cancer care, including the expectation for long-term survival and how to treat patients in remission. Read More ›
Dr Morganna Freeman outlines some of the criteria used in deciding which patients will most benefit from immunotherapy. Read More ›
By Jane Morgan
Several immune checkpoint inhibitors are now approved for patients with non–small-cell lung cancer, giving hope to patients living with this disease. Read More ›
By Dana Taylor
After many years in development, the newest type of immunotherapy known as CAR T-cell therapy (or gene therapy) is becoming a mainstream treatment in some types of blood cancer, specifically in leukemia and lymphoma. Read More ›
By Dana Taylor
Immunotherapy brings new hope for patients with Merkel-cell carcinoma, a rare type of skin cancer with few treatment options. Read More ›
New developments in immunotherapy drugs continue to create buzz in the cancer community and beyond. This special issue discusses key developments in immunotherapy, highlighting new advances and providing resources for patients, their family members, and their oncology navigators. Read More ›
By Jane Morgan
Several immune checkpoint inhibitors are now approved for patients with non-small-cell lung cancer, giving hope to patients living with this disease. Read More ›
“CAR T-cell therapy provides an exciting and additional option for patients who have failed more traditional regimens,” says Dr. Gwen Nichols, Chief Medical Officer for Leukemia & Lymphoma Society. Read More ›
By Wayne Kuznar
The National Comprehensive Cancer Care Network and the American Society of Clinical Oncology recently issued the first set of recommendations for the management of immunotherapy side-effects. Read More ›